Brain Tumor
Conditions
Brief summary
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Detailed description
Nine to forty-two (42 patients only if every cohort required expansion) total patients were planned for the main BN-16-01 phase 0/1 study to explore the ability of letrozole to penetrate the blood brain barrier and gliomas. As of November 2023 The BN-16-01 main study has completed active recruitment (20 subjects were accrued) and all safety and pharmacokinetics data have been analyzed with subsequent publications pending. Characterization of the safety and pharmacokinetics of letrozole in combination with standard of care treatments, such as TMZ has been completed for the main study and provides the rationale for initiation of a sub-study. A new sub-study Letrozole and Temozolomide expansion cohort has been opened to accrual. This Phase 1 expansion cohort of letrozole 15mg administered in combination with 50 mg/m2 metronomic temozolomide (TMZ) in patients with high grade gliomas. 19 subjects total (2 historical subjects from the main study and 17 new accruals) will be enrolled into this expansion cohort.
Interventions
Administration: Letrozole will be given orally once daily.
DRUGTemozolomide
50 mg/m2 TMZ administered orally once daily
Sponsors
University of Cincinnati
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma with plan for resection or biopsy. \- Inclusion #1 for Sub-study Only: Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma. 2. Age \>18 years. 3. ECOG performance status 0 -2 (Karnofsky \>60%, see Appendix A). 4. CBC/differential obtained within 28 days prior to registration on study, with adequate bone marrow function defined as follows: * Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3; * Platelets ≥ 100,000 cells/mm3; * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable). 5. Adequate hepatic function, defined as follows: * Total bilirubin \< 2 x institutional ULN within 14 days prior to registration; * AST or ALT \< 3 x institutional ULN within 14 days prior to registration. 6. Adequate renal function, defined as GFR \> 30 ml/min or Cr \< 1.5. 7. Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential. 8. Imaging prior to treatment including MRI of brain (with contrast preferred but not required). 9. Ability to understand and the willingness to sign a written informed consent document. 10. Inclusion #10 for Sub-study Only: Measurable disease per RANO criteria within 28 days of starting treatment on this study.
Exclusion criteria
1. Patients may not be receiving any other investigational agents. 2. History of allergic reactions attributed to letrozole or other agents used in study. Exclusion #2 for Sub-study Only: History of allergic reactions attributed to letrozole or TMZ. 3. Uncontrolled intercurrent illness including, but not limited to, ongoing significant or serious active cardiovascular disease (CHF exacerbation, unstable angina or MI in last 6 months), or infection including the diagnosis of AIDS or active hepatitis B or C infection, or psychiatric illness or medical or personal conditions that in the opinion of the investigator would limit the patient's ability to participate. 4. Patients attempting to conceive, and pregnant or nursing women are excluded from this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Letrozole AUC in tumor tissue. | 5 days | Pharmacokinetic modeling will be used to determine the overall AUC in the tumor tissue to assess for letrozole penetration through blood brain barrier. |
| Progression free survival in letrozole and temozolomide combination | 6 months | Sub-study expansion cohort only: Progression free survival using RANO criteria at 6 months from the start of the combination of 15 mg letrozole and 50 mg/m2 temozolomide. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | The time patients remain on treatment until 30 days after treatment completed | The number of patients with treatment related toxicity will be assessed using CTCAE v4.0 |
| Progression free Survival | From start of treatment until time of progression assessed up to 1 year | Patients will be followed for response using RANO criteria to determine time from start of treatment to progression. |
| Overall Survival | From start of treatment until time of death assessed up to 1 year | Patients will be followed from start of treatment until time of death |
Countries
United States
Contacts
Primary ContactUC Cancer Center Clinical Trials Office
Outcome results
None listed